Curiously, the tumor protection induced by metformin was not altered when CD25+ cells were depleted, suggesting that CD4+Foxp3+IL-10+ T cells induced by metformin treatment do not impair the observed antitumor effect. The gene discussed is FOXP3; the disease is neoplasm.